» Articles » PMID: 39971396

The Impact of Lung Surgery, with or Without (neo-)adjuvant Therapy, on Physical Functioning in Patients with Nonsmall Cell Lung Cancer: a Scoping Review

Overview
Journal Eur Respir Rev
Specialty Pulmonary Medicine
Date 2025 Feb 19
PMID 39971396
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with early stage (I-IIIA) nonsmall cell lung cancer (NSCLC) are typically treated surgery, often accompanied by (neo-)adjuvant therapy. These interventions impose a significant burden on patients and potentially impact their physical functioning (PF). The impact on PF remains uncertain and existing evidence has not yet been systematically outlined.

Objective: This scoping review aimed to synthesise evidence concerning the effects of lung surgery, with or without (neo-)adjuvant therapy, on the PF of patients with NSCLC.

Methods: PubMed, Web of Science and Cochrane databases were systematically searched from inception until 1 July 2023. A comprehensive framework based on the International Classification of Functioning, Disability, and Health was used to define various aspects of PF. Longitudinal studies, reporting PF prior to and after NSCLC treatment, and cross-sectional studies reporting PF after treatment were included.

Results: 85 included studies assessed the effects of surgery with (n=7) or without (n=78) (neo-) adjuvant therapy on body function (n=29), activity (n=67) and/or participation (n=15). 98% of reported outcomes within the longitudinal studies indicate a decline in PF, with 52% demonstrating significant deteriorations, with follow-up times ranging from immediately post-operative up to 1 year after treatment. Cross-sectional studies show impaired PF in 71% of reported outcomes.

Conclusion: PF of patients with NSCLC tends to deteriorate following lung surgery, irrespective of additional (neo-)adjuvant therapy. While the negative impact of lung surgery on ICF categories of "body function" and "activity" have been described to some depth, insights into the impact on "participation" are lacking.

References
1.
Bredda Saad I, Botega N, Toro I . Predictors of quality-of-life improvement following pulmonary resection due to lung cancer. Sao Paulo Med J. 2007; 125(1):46-9. PMC: 11014704. DOI: 10.1590/s1516-31802007000100009. View

2.
Hopstaken J, de Ruiter J, Damhuis R, de Langen A, van Diessen J, Klomp H . Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives. Cancer Treat Res Commun. 2021; 28:100404. DOI: 10.1016/j.ctarc.2021.100404. View

3.
Holland A, Cox N, Houchen-Wolloff L, Rochester C, Garvey C, ZuWallack R . Defining Modern Pulmonary Rehabilitation. An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc. 2021; 18(5):e12-e29. PMC: 8086532. DOI: 10.1513/AnnalsATS.202102-146ST. View

4.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

5.
Huang C, Hsieh M, Wu Y, Hsieh P, Yang M, Tzeng I . Chronic obstructive pulmonary disease assessment test for the measurement of deterioration and recovery of health status of patients undergoing lung surgery. Thorac Cancer. 2022; 13(4):613-623. PMC: 8841704. DOI: 10.1111/1759-7714.14306. View